drug · small molecule

icosapent ethyl

Marketedupdated 3mo ago

by KD Pharma Group SA🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 6 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying icosapent ethyl

phase3A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)recruitingn=266
phase3A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)recruitingn=876
—A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia Arecruitingn=25
—Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedurerecruitingn=3,574
phase3Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)recruitingn=3,500
phase2Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLMnot yet recruitingn=60
phase3A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASHrecruitingn=1,200
phase2Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcomaactive not recruitingn=80

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

May 31, 2027

292 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (122)

Jun 28, 2033method-of-use (U-2701)US 10278935
Jun 28, 2033method-of-use (U-2701)US 10278935
Jun 28, 2033method-of-use (U-2702)US 10278936
Jun 28, 2033method-of-use (U-2702)US 10278936
Jun 28, 2033method-of-use (U-2703)US 10278937
Jun 28, 2033method-of-use (U-2703)US 10278937
Jun 28, 2033method-of-use (U-2704)US 10383840
Jun 28, 2033method-of-use (U-2704)US 10383840
Jun 28, 2033method-of-use (U-2743)US 10555924
Jun 28, 2033method-of-use (U-2743)US 10555924
Jun 28, 2033method-of-use (U-2744)US 10555925
Jun 28, 2033method-of-use (U-2744)US 10555925
Jun 28, 2033method-of-use (U-2756)US 10568861
Jun 28, 2033method-of-use (U-2756)US 10568861
Jun 28, 2033method-of-use (U-2762)US 10576054
Jun 28, 2033method-of-use (U-2762)US 10576054
Jun 28, 2033method-of-use (U-2841)US 10668042
Jun 28, 2033method-of-use (U-2841)US 10668042
Jun 28, 2033method-of-use (U-2960)US 10786478
Jun 28, 2033method-of-use (U-2960)US 10786478
Jun 28, 2033method-of-use (U-2962)US 10792270
Jun 28, 2033method-of-use (U-2962)US 10792270
Jun 28, 2033method-of-use (U-3053)US 10894028
Jun 28, 2033method-of-use (U-3053)US 10894028
Jun 28, 2033method-of-use (U-3126)US 11000499
Jun 28, 2033method-of-use (U-3126)US 11000499
Jun 28, 2033method-of-use (U-3221)US 11116742
Jun 28, 2033method-of-use (U-3221)US 11116742
Jun 28, 2033method-of-use (U-3358)US 11298333
Jun 28, 2033method-of-use (U-3358)US 11298333
Jun 28, 2033method-of-use (U-2841)US 11369582
Jun 28, 2033method-of-use (U-2841)US 11369582
Jun 28, 2033method-of-use (U-2696)US 9603826
Jun 28, 2033method-of-use (U-2696)US 9603826
Jun 28, 2033method-of-use (U-2697)US 9610272
Jun 28, 2033method-of-use (U-2697)US 9610272
Jun 28, 2033method-of-use (U-2698)US 9623001
Jun 28, 2033method-of-use (U-2698)US 9623001
Jun 28, 2033method-of-use (U-2697)US 9693984
Jun 28, 2033method-of-use (U-2697)US 9693984
Jun 28, 2033method-of-use (U-2696)US 9693985
Jun 28, 2033method-of-use (U-2696)US 9693985
Jun 28, 2033method-of-use (U-2698)US 9693986
Jun 28, 2033method-of-use (U-2698)US 9693986
Jun 28, 2033method-of-use (U-2699)US 9918954
Jun 28, 2033method-of-use (U-2699)US 9918954
Jun 15, 2030method-of-use (U-2688)US 108427683.8y
Jun 15, 2030method-of-use (U-2688)US 108427683.8y
Jun 15, 2030method-of-use (U-2688)US 84100863.8y
Jun 15, 2030method-of-use (U-2688)US 84100863.8y
Jun 15, 2030method-of-use (U-2690)US 84554723.8y
Jun 15, 2030method-of-use (U-2694)US 86692453.8y
Jun 15, 2030method-of-use (U-2694)US 86692453.8y
Jun 15, 2030method-of-use (U-2690)US 87100413.8y
Jun 15, 2030method-of-use (U-2690)US 87100413.8y
Apr 29, 2030method-of-use (U-2690)US 100105173.7y
Apr 29, 2030method-of-use (U-2690)US 100105173.7y
Apr 29, 2030method-of-use (U-2700)US 102652873.7y
Apr 29, 2030method-of-use (U-2700)US 102652873.7y
Apr 29, 2030method-of-use (U-2961)US 107922673.7y
Apr 29, 2030method-of-use (U-2961)US 107922673.7y
Apr 29, 2030method-of-use (U-2997)US 108427663.7y
Apr 29, 2030method-of-use (U-2997)US 108427663.7y
Apr 29, 2030method-of-use (U-3052)US 108816323.7y
Apr 29, 2030method-of-use (U-3052)US 108816323.7y
Apr 29, 2030method-of-use (U-3209)US 111034773.7y
Apr 29, 2030method-of-use (U-3209)US 111034773.7y
Apr 29, 2030method-of-use (U-3240)US 111545263.7y
Apr 29, 2030method-of-use (U-3240)US 111545263.7y
Apr 29, 2030method-of-use (U-3292)US 112135043.7y
Apr 29, 2030method-of-use (U-3292)US 112135043.7y
Apr 29, 2030method-of-use (U-3669)US 117175043.7y
Apr 29, 2030method-of-use (U-3669)US 117175043.7y
Apr 29, 2030formulationUS 82985543.7y
Apr 29, 2030formulationUS 82985543.7y
Apr 29, 2030method-of-use (U-1287)US 84450033.7y
Apr 29, 2030method-of-use (U-1287)US 84450033.7y
Apr 29, 2030method-of-use (U-1287)US 84450133.7y
Apr 29, 2030method-of-use (U-1287)US 84450133.7y
Apr 29, 2030method-of-use (U-2689)US 84549943.7y
Apr 29, 2030method-of-use (U-2689)US 84549943.7y
Apr 29, 2030method-of-use (U-1287)US 85012253.7y
Apr 29, 2030method-of-use (U-1287)US 85012253.7y
Apr 29, 2030method-of-use (U-1287)US 85515213.7y
Apr 29, 2030method-of-use (U-1287)US 85515213.7y
Apr 29, 2030method-of-use (U-1287)US 85636083.7y
Apr 29, 2030method-of-use (U-1287)US 85636083.7y
Apr 29, 2030method-of-use (U-2691)US 86175933.7y
Apr 29, 2030method-of-use (U-2691)US 86175933.7y
Apr 29, 2030method-of-use (U-1287)US 86175943.7y
Apr 29, 2030method-of-use (U-1287)US 86175943.7y
Apr 29, 2030method-of-use (U-2689)US 86181663.7y
Apr 29, 2030method-of-use (U-2692)US 86234063.7y
Apr 29, 2030method-of-use (U-1478)US 86234063.7y
Apr 29, 2030method-of-use (U-2693)US 86420773.7y
Apr 29, 2030method-of-use (U-2693)US 86420773.7y
Apr 29, 2030method-of-use (U-2689)US 86918713.7y
Apr 29, 2030method-of-use (U-2689)US 86918713.7y
Apr 29, 2030method-of-use (U-2691)US 87031853.7y
Apr 29, 2030method-of-use (U-2691)US 87031853.7y
Apr 29, 2030method-of-use (U-2689)US 87094753.7y
Apr 29, 2030method-of-use (U-2689)US 87094753.7y
Feb 9, 2030method-of-use (U-4105)US 121717383.5y
Feb 9, 2030method-of-use (U-4105)US 121717383.5y
Feb 9, 2030method-of-use (U-1287)US 83994463.5y
Feb 9, 2030method-of-use (U-1287)US 84153353.5y
Feb 9, 2030method-of-use (U-1287)US 84153353.5y
Feb 9, 2030method-of-use (U-1287)US 84263993.5y
Feb 9, 2030method-of-use (U-1287)US 84263993.5y
Feb 9, 2030method-of-use (U-1287)US 84315603.5y
Feb 9, 2030method-of-use (U-1287)US 85189293.5y
Feb 9, 2030method-of-use (U-1287)US 85189293.5y
Feb 9, 2030method-of-use (U-1287)US 85246983.5y
Feb 9, 2030method-of-use (U-1287)US 85246983.5y
Feb 9, 2030method-of-use (U-1287)US 85463723.5y
Feb 9, 2030method-of-use (U-1287)US 85463723.5y
Feb 9, 2030method-of-use (U-2695)US 86801443.5y
Feb 9, 2030method-of-use (U-2695)US 86801443.5y
Sep 25, 2027method-of-use (U-2706)US 91988921.1y
Sep 25, 2027method-of-use (U-2706)US 91988921.1y
May 31, 2027method-of-use (U-2707)US 9700537292d
May 31, 2027method-of-use (U-2707)US 9700537292d

News(10)

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…
fiercebiotech · 14d ago
‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug
A new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.
fiercebiotech · 14d ago
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
biospace · 20d ago
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharmaceuticals.
fiercebiotech · 25d ago
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
biopharma_dive · 1mo ago
Generic drugmakers gain key victory in ‘skinny label’ patent case
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
biopharma_dive · 2mo ago
Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice
Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.
onclive · 2mo ago
FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.
onclive · 2mo ago
FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma
The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.
onclive · 2mo ago
Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.
onclive · 2mo ago

view all news mentions →

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 49m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

News(10)

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK has unveiled an ambitious three-year plan to divert resources to its late-stage R&D programs and shift its research headquarters—but CEO Luke Miels is being tight-lipped about the extent of any…

fiercebiotech · 14d ago

‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug

A new biotech has come into view with a $118 million series B and a vision for making the front of the eye front-of-mind.

fiercebiotech · 14d ago

Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts

With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.

biospace · 20d ago

Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador

Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharmaceuticals.

fiercebiotech · 25d ago

Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program

The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.

biopharma_dive · 1mo ago

Generic drugmakers gain key victory in ‘skinny label’ patent case

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

biopharma_dive · 2mo ago

Dr Loghavi on the Significance of Updated WHO Diagnostic Criteria for AML in Clinical Practice

Sanam Loghavi, MD, discusses updated WHO diagnostic criteria for acute myeloid leukemia and its significance for diagnoses and treatment selection.

onclive · 2mo ago

FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML

The FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.

onclive · 2mo ago

FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma

The FDA granted accelerated approval to sonrotoclax for relapsed/refractory mantle cell lymphoma after at least 2 lines of systemic therapy.

onclive · 2mo ago

Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML

Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.

onclive · 2mo ago

view all news mentions →

icosapent ethyl

🐶 often sniffed alongside

all catalysts(0)

Trials studying icosapent ethyl

Patent cliff

patents (122)

News(10)

Report a data issue

comments(0)

icosapent ethyl

🐶 often sniffed alongside

all catalysts(0)

Trials studying icosapent ethyl

Patent cliff

patents (122)

News(10)

Report a data issue

comments(0)